TY - JOUR
T1 - Long-term Outcomes of Amniotic Membrane Transplantation for Repair of Leaking Glaucoma Filtering Blebs
AU - Rauscher, Frederick M.
AU - Barton, Keith
AU - Budenz, Donald L.
AU - Feuer, William J.
AU - Tseng, Scheffer C.G.
N1 - Funding Information:
This study was supported by grant P30-EY014801 from the National Institutes of Health, Bethesda, Maryland, and by an unrestricted grant to the University of Miami from Research to Prevent Blindness, Inc, New York, New York. The authors indicate no financial conflict of interest. Dr Tseng has been issued a patent on preparation and clinical uses of amniotic membrane and has a proprietary interest in Bio-Tissue, Inc, which sells amniotic membrane. Involved in design and conduct of study (D.L.B., K.B., F.M.R., S.C.G.T.); data analysis (F.M.R., W.J.F., D.L.B., K.B., S.C.G.T.); and preparation and review of the manuscript (F.M.R., K.B., D.L.B., W.J.F., S.C.G.T.).
PY - 2007/6
Y1 - 2007/6
N2 - Purpose: To report long-term results of human preserved amniotic membrane transplant (AMT) vs conjunctival advancement for repair of late-onset glaucoma filtering bleb leakage. Design: Randomized, controlled trial (n = 30). Methods: Rates of bleb failure (reoperation for glaucoma or recurrent bleb leak) were compared. Results: Median follow-up was 80 months. Final intraocular pressure (IOP) was 10.9 ± 0.9 mm Hg with AMT and 12.7 ± 1.3 mm Hg with conjunctival advancement (P = .28). The number of glaucoma medications and final visual acuities were similar between groups. Bleb vascularity was significantly less with AMT (P = .02). Seven failures occurred with AMT, four requiring reoperation for bleb leakage and three requiring reoperation for glaucoma. Four failures occurred with conjunctival advancement, one requiring reoperation for leakage and three requiring reoperation for glaucoma. Kaplan-Meier survival curves were statistically similar between groups, with a trend favoring conjunctival advancement (P = .44). Conclusions: Although prone to early releakage, AMT may be a suitable alternative to conjunctival advancement in the long-term.
AB - Purpose: To report long-term results of human preserved amniotic membrane transplant (AMT) vs conjunctival advancement for repair of late-onset glaucoma filtering bleb leakage. Design: Randomized, controlled trial (n = 30). Methods: Rates of bleb failure (reoperation for glaucoma or recurrent bleb leak) were compared. Results: Median follow-up was 80 months. Final intraocular pressure (IOP) was 10.9 ± 0.9 mm Hg with AMT and 12.7 ± 1.3 mm Hg with conjunctival advancement (P = .28). The number of glaucoma medications and final visual acuities were similar between groups. Bleb vascularity was significantly less with AMT (P = .02). Seven failures occurred with AMT, four requiring reoperation for bleb leakage and three requiring reoperation for glaucoma. Four failures occurred with conjunctival advancement, one requiring reoperation for leakage and three requiring reoperation for glaucoma. Kaplan-Meier survival curves were statistically similar between groups, with a trend favoring conjunctival advancement (P = .44). Conclusions: Although prone to early releakage, AMT may be a suitable alternative to conjunctival advancement in the long-term.
UR - http://www.scopus.com/inward/record.url?scp=34248593350&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=34248593350&partnerID=8YFLogxK
U2 - 10.1016/j.ajo.2007.01.016
DO - 10.1016/j.ajo.2007.01.016
M3 - Article
C2 - 17524779
AN - SCOPUS:34248593350
VL - 143
SP - 1052
EP - 1054
JO - American Journal of Ophthalmology
JF - American Journal of Ophthalmology
SN - 0002-9394
IS - 6
ER -